目的 观察渴络欣胶囊联合替米沙坦治疗2型糖尿病肾病的临床疗效。方法 选取2015年1月-2015年12月西安市第九医院收治的2型糖尿病肾病患者106例，随机分为对照组和治疗组，每组各53例。对照组口服替米沙坦片，80 mg/次，1次/d。治疗组在对照组治疗基础上口服渴络欣胶囊，4粒/次，3次/d。两组均连续治疗8周。观察两组的临床疗效，同时比较两组治疗前后三酰甘油（TG）、胆固醇（TC）、24 h尿蛋白、尿白蛋白排泄率（UAER）。结果 治疗后，对照组和治疗组的总有效率分别为81.13%、92.45%，两组比较差异有统计学意义（P<0.05）。治疗后，两组TG、TC、24 h尿蛋白定量、UAER均显著降低，同组治疗前后差异有统计学意义（P<0.05）；且治疗组这些观察指标的降低程度优于对照组，两组比较差异有统计学意义（P<0.05）。结论 渴络欣胶囊联合替米沙坦治疗2型糖尿病肾病具有较好的临床疗效，可改善生化指标，具有一定的临床推广应用价值。

Objective To observe the clinical curative effect of Keluoxin Capsules combined with telmisartan in treatment of type 2 diabetic nephropathy. Methods Patients (106 cases) with type 2 diabetic nephropathy in Ninth Hospital of Xi'an from January 2015 to December 2015 were randomly divided into control and treatment groups, and each group had 53 cases. The patients in the control group were po administered with Telmisartan Tablets, 80 mg/time, once daily. The patients in the treatment group were po administered with Keluoxin Capsules on the basis of the control group, 4 grains/time, three times daily. The patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the changes of TG, TC, 24 h urine protein, and UAER in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.13% and 92.45%, respectively, and there were differences between two groups (P<0.05). After treatment, TG, TC, 24 h urine protein, and UAER in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Keluoxin Capsules combined with telmisartan has clinical curative effect in treatment of type 2 diabetic nephropathy, and can improve the biochemical indicators, with a certain clinical application value.